TheRealReal REAL 深 滬
已收盤 02-06 16:00:00 美东时间
13.09
+0.520
+4.14%
華盛通- 最 高13.26
- 今 開12.65
- 成交量 245.35万股
- 最 低 12.51
- 昨 收 12.57
- 總市值 15.27亿
- 52周最高 17.3922
- 市盈率 靜 --
- 換手率 2.10%
- 52周最低 4.61
- 委 比 73.85%
- 總股本 1.17亿
- 歷史最高 30.22
- 量 比 0.71
- 振 幅 5.97%
- 歷史最低 1.00
- 每 手 1
- 風險率 3.89%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多The RealReal Inc. announces upcoming earnings release and conference call
The RealReal Inc. announces upcoming earnings release and conference call The RealReal Inc. will release its financial results for the fourth quarter and full year ended December 31, 2025, after the market closes on February 26, 2026. A conference call to review these results will be held at 2:00 p.
01-28 08:14
The RealReal Announces Timing of Its Fourth Quarter and Full Year 2025 Earnings Conference Call
The RealReal, the world's largest online marketplace for authenticated luxury goods, will release its fourth-quarter and full-year 2025 financial results on February 26, 2026, after market close. A conference call to discuss the results will be held at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time), with a live webcast available at investor.therealreal.com.
01-28 00:14
美股大行评级 | 潜在涨幅258.31%！Tempest Therapeutics获HC Wainwright上调评级至"买入"，目标价11美元
今日重点评级关注：HC Wainwright & Co.：上调Tempest Therapeutics评级至"买入"，目标价11美元；Guggenheim：维持Sportradar Gr"买入"评级，目标价从34美元升至35美元
01-23 19:46
Keybanc Maintains Overweight on RealReal, Raises Price Target to $20
Keybanc analyst Ashley Owens maintains RealReal (NASDAQ:REAL) with a Overweight and raises the price target from $16 to $20.
01-22 20:39
美股大行评级 | 潜在涨幅197.4%！奥麦罗制药获HC Wainwright升目标价至40美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持奥麦罗制药"买入"评级，目标价从20美元升至40美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从26美元升至27美元
01-09 20:22
UBS Maintains Neutral on RealReal, Raises Price Target to $16
UBS analyst Kunal Madhukar maintains RealReal (NASDAQ:REAL) with a Neutral and raises the price target from $14 to $16.
01-09 00:49
美股大行评级 | 潜在涨幅1391.05%！Maison Solutions获Ascendiant Capital升目标价至4.5美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Maison Solutions"买入"评级，目标价从4.25美元升至4.5美元；HC Wainwright & Co.：维持Greenwich LifeSciences"买入"评级，目标价从39美元升至50美元
2025-12-31 10:25
BTIG Maintains Buy on RealReal, Raises Price Target to $18
BTIG analyst Marvin Fong maintains RealReal (NASDAQ:REAL) with a Buy and raises the price target from $15 to $18.
2025-12-30 21:23
BTIG thinks RealReal's strong 2025 rally can extend into 2026
BTIG lifted its price target on The RealReal (REAL) to $18 on its view that the strong 2025 rally can extend into 2026. Analyst Marvin Fong said the firm continues to target a 4X EV/gross profit multi...
2025-12-30 19:47
美股大行评级 | 潜在涨幅263.64%！Milestone Pharmaceuticals获富国银行升目标价至8美元，维持"超配"评级
今日重点评级关注：富国银行：维持Milestone Pharmaceuticals"超配"评级，目标价从4美元升至8美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从31美元升至33美元
2025-12-17 10:46
